# Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction

> **NCT01781390** · PHASE2 · COMPLETED · sponsor: **Mesoblast, Inc.** · enrollment: 106 (actual)

## Conditions studied

- Acute Myocardial Infarction

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** Mesenchymal Precursor Cells (MPC) 12.5 M
- **BIOLOGICAL:** Mesenchymal Precursor Cells (MPC) 25 M

## Key facts

- **NCT ID:** NCT01781390
- **Lead sponsor:** Mesoblast, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-11
- **Primary completion:** 2021-04-06
- **Final completion:** 2021-04-06
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2022-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01781390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01781390, "Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01781390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*